Owlstone Medical, the innovative company which promises to revolutionise the diagnosis of cancer by simply analysing a patient’s breath has been given a major funding boost.
With genetic analysis and diagnostic tests now available via mail order, how will this trend towards the proactive consumer impact the evolution of health management?
Angle hopes Parsortix will be first approved cell-based liquid biopsy.
Breath Biopsy will be tested in its ability to detect several cancers earlier than traditional methods.
Circulating tumour cell test could help select drug therapy.
Partner Fund Management agrees to drop lawsuits.
CMS report describes failures meeting its own quality control procedures.
Abbott’s test is now the first to receive FDA commercial authorisation in an emergency use setting.
